Professional Marketing briefs

Share this article:
Access Pharma signed an agreement with iMedicor for the North American commercial launch of MuGard, its FDA approved mucoadhesive oral rinse for the management of oral mucositis and stomatitis caused by radiotherapy and/or chemotherapy. MuGard is being commercially launched worldwide, with initial launches in the United Kingdom, Germany, Italy, Norway and Greece having been previously announced.   
    
Ariad Healthcare will be EMD Serono's lead marketing agency in Canada for Multibionta Probiotic Multivitamin beginning in 2010. Ariad's work on Multibionta began earlier this spring, and marketing initiatives are now being deployed in support of its retail launch.
 
Aptilon Corporation inked a deal with Direct Medical Data (DMD) to acquire all DMD assets related to its healthcare marketing services. DMD has healthcare professional and facility databases in the US. DMD's database of physician email addresses covers more than 560,000 individual physicians. DMD's healthcare provider database resources will support the expansion of its online physician network while Aptilon's existing customer relationships will open new sales channels for DMD services.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?